We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Regional Observatory on Metabolic Syndrome- LAZIO (ORSA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00689455
Recruitment Status : Completed
First Posted : June 3, 2008
Last Update Posted : December 3, 2010
Information provided by:

Brief Summary:
The aim of the study, is to assess the prevalence of Metabolic Syndrome in Italy on a regional basis, defined according to NCEP/ATPIII Guidelines criteria.

Condition or disease
Metabolic Syndrome

Study Type : Observational
Actual Enrollment : 1574 participants
Time Perspective: Cross-Sectional
Official Title: Regional Observatory on Metabolic Syndrome in Italy- LAZIO
Study Start Date : October 2007
Primary Completion Date : December 2008
Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary care population

Primary Outcome Measures :
  1. Prevalence of Metabolic Syndrome in Primary Care Population. [ Time Frame: At Visit ]

Secondary Outcome Measures :
  1. Concomitant presence of other CV risk factors. [ Time Frame: At Visit ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary care clinic

Inclusion Criteria:

  • lipid profile in the last year
  • Signed informed consent

Exclusion Criteria:

  • Subjects with serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's successful participation in the study
  • Pregnancy or breast feeding
  • Subject who are unwilling or unable to provide the informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00689455

Research Site
Rieti, Italy
Research Site
ROme, Italy
Research Site
Viterbo, Italy
Sponsors and Collaborators
Study Chair: Volpe Massimo, MD, FACC Cardiology Dept. Director, Sapienza University, Sant' Andrea Hospital, Rome

Responsible Party: Mario Mangrella MD Medical Manager, Cardiometabolic Team, AstraZeneca S.p.A.
ClinicalTrials.gov Identifier: NCT00689455     History of Changes
Other Study ID Numbers: NIS-CIT-DUM-2008/2
First Posted: June 3, 2008    Key Record Dates
Last Update Posted: December 3, 2010
Last Verified: December 2010

Keywords provided by AstraZeneca:
Metabolic Syndrome
Waist Circumference

Additional relevant MeSH terms:
Metabolic Syndrome X
Pathologic Processes
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases